Guggenheim Cuts InflaRx (NASDAQ:IFRX) Price Target to $14.00

InflaRx (NASDAQ:IFRX) had its price target cut by Guggenheim from $22.00 to $14.00 in a report issued on Friday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts have also recently weighed in on IFRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research note on Monday, December 29th. Leerink Partners reiterated a “market perform” rating and issued a $2.00 price target (down from $5.00) on shares of InflaRx in a research note on Wednesday, December 3rd. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of InflaRx in a report on Tuesday, December 30th. Finally, Raymond James Financial restated an “outperform” rating on shares of InflaRx in a research report on Wednesday, December 31st. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.17.

InflaRx Price Performance

IFRX stock opened at $0.94 on Friday. InflaRx has a 1-year low of $0.71 and a 1-year high of $1.94. The business has a 50 day simple moving average of $0.93 and a two-hundred day simple moving average of $1.14. The company has a market capitalization of $63.69 million, a price-to-earnings ratio of -1.24 and a beta of 1.48.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.17). The company had revenue of ($0.04) million for the quarter, compared to the consensus estimate of $0.03 million. Sell-side analysts anticipate that InflaRx will post -1.04 EPS for the current fiscal year.

Institutional Investors Weigh In On InflaRx

Hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC lifted its position in InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares during the last quarter. HRT Financial LP bought a new stake in shares of InflaRx in the 4th quarter worth about $47,000. Concurrent Investment Advisors LLC raised its position in shares of InflaRx by 56.9% during the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after buying an additional 19,200 shares in the last quarter. Insigneo Advisory Services LLC purchased a new stake in shares of InflaRx during the 4th quarter valued at about $61,000. Finally, Quadrature Capital Ltd bought a new position in shares of InflaRx in the 4th quarter valued at about $104,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

More InflaRx News

Here are the key news stories impacting InflaRx this week:

• Positive Sentiment: Company highlights promising Phase 2a izicopan data, progress toward Phase 2b readiness in hidradenitis suppurativa (HS), plans for PK bridging in China, active collaborator discussions, and a spring Capital Markets Day to outline the development path—these clinical and strategic updates are the main near‑term catalysts. InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
• Positive Sentiment: Guggenheim maintained a Buy rating while lowering its price target from $22 to $14 — the cut reduces upside vs prior expectations but the firm still signals conviction in the story, which can support the stock. Guggenheim price target note (Benzinga)
• Positive Sentiment: HC Wainwright continues to carry a Buy rating with a $6 target and published near‑term EPS estimates (Q1 2026: -$0.14; Q2 2026: -$0.13), providing analyst support and a clear set of expectations for upcoming quarters. HC Wainwright estimates (MarketBeat)
• Neutral Sentiment: InflaRx reported Q4 EPS of ($0.17), which met consensus, reducing near‑term headline risk from the print itself. Press Release
• Neutral Sentiment: Market coverage and public filings (Business Insider / GlobeNewswire) provide a fuller corporate update on milestones and timelines; these items clarify strategy but do not immediately alter cash or clinical risk. InflaRx full‑year results (Business Insider)
• Negative Sentiment: Revenue remains negligible and the company reported revenue below estimates; InflaRx is still loss‑making with consensus full‑year EPS around -$1.04, underlining ongoing financing and execution risk. Zacks: Q4 loss, revenue miss
• Negative Sentiment: Cash, cash equivalents and marketable securities totaled €46.2M at 12/31/25, which the company says funds operations to mid‑2027 — this finite runway implies potential dilution or financing needs if clinical programs extend or expand. InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.